- Home
- BRNS vs CCEL Comparison
BRNS vs CCEL Comparison
Compare BRNS & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- CCEL
- Stock Information
- Founded
- BRNS 2016
- CCEL 1989
- Country
- BRNS United Kingdom
- CCEL United States
- Employees
- BRNS N/A
- CCEL N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- BRNS Health Care
- CCEL Health Care
- Exchange
- BRNS Nasdaq
- CCEL Nasdaq
- Market Cap
- BRNS 52.0M
- CCEL 53.9M
- IPO Year
- BRNS 2021
- CCEL 1997
- Fundamental
- Price
- BRNS $1.17
- CCEL $6.26
- Analyst Decision
- BRNS Strong Buy
- CCEL
- Analyst Count
- BRNS 2
- CCEL 0
- Target Price
- BRNS $4.00
- CCEL N/A
- AVG Volume (30 Days)
- BRNS 39.3K
- CCEL 3.5K
- Earning Date
- BRNS 11-07-2024
- CCEL 10-22-2024
- Dividend Yield
- BRNS N/A
- CCEL N/A
- EPS Growth
- BRNS N/A
- CCEL N/A
- EPS
- BRNS N/A
- CCEL N/A
- Revenue
- BRNS N/A
- CCEL $31,641,636.00
- Revenue This Year
- BRNS $27.18
- CCEL $3.70
- Revenue Next Year
- BRNS N/A
- CCEL $10.57
- P/E Ratio
- BRNS N/A
- CCEL N/A
- Revenue Growth
- BRNS N/A
- CCEL 1.93
- 52 Week Low
- BRNS $1.11
- CCEL $3.67
- 52 Week High
- BRNS $5.10
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- BRNS 40.45
- CCEL 45.11
- Support Level
- BRNS $1.15
- CCEL $6.29
- Resistance Level
- BRNS $1.35
- CCEL $6.80
- Average True Range (ATR)
- BRNS 0.07
- CCEL 0.28
- MACD
- BRNS 0.00
- CCEL 0.02
- Stochastic Oscillator
- BRNS 14.29
- CCEL 9.71
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.